Drug profile

The FDA adverse-event record for Mannheimia Haemolytica Bacterial Extract-Toxoid

20 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mannheimia Haemolytica Bacterial Extract-Toxoid. See the species affected, top reactions, and outcomes below.

20
adverse-event reports
70.0%
death-coded share
Cattle
most-reported species
12
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
14
Deaths Reported
70.0%
Death Rate

Active Ingredients

Mannheimia Haemolytica Bacterial Extract-Toxoid

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Cattle 20

Most Affected Breeds

Cattle (unknown) 9
Crossbred Bovine/Cattle 4
Mixed (Cattle) 3
Aberdeen Angus 2
Holstein-Friesian also known as Holstein 1
Red Angus 1

Most Reported Reactions

Death 12
Lameness 5
Eye disorder NOS (for photophobia see 'neurological') 4
Respiratory tract disorder NOS 4
Skin abscess 4
Claw / hoof / nail disorder NOS 4
Pneumonia 4
Bloated 3
Laboured breathing 3
Lack of efficacy - NOS 3
Laceration 3
Pink eye 2

Outcome Breakdown

Died
14 (46.7%)
Outcome Unknown
13 (43.3%)
Recovered/Normal
2 (6.7%)
Ongoing
1 (3.3%)

Mannheimia Haemolytica Bacterial Extract-Toxoid Adverse Event Insights

20 reports name Mannheimia Haemolytica Bacterial Extract-Toxoid; 14 recorded a death outcome (70.0% of reported events, not a population-level mortality rate). Active ingredient: Mannheimia Haemolytica Bacterial Extract-Toxoid. Administration routes: Unknown, Subcutaneous, Parenteral.

By species: Cattle (20 reports). By breed: Cattle (unknown) (9), Crossbred Bovine/Cattle (4), Mixed (Cattle) (3).

Leading clinical signs: Death (12), Lameness (5), Eye disorder NOS (for photophobia see 'neurological') (4), Respiratory tract disorder NOS (4). Outcome, 30 coded reports: Died leads at 46.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.